216 related articles for article (PubMed ID: 30149266)
1. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
[TBL] [Abstract][Full Text] [Related]
3. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
[TBL] [Abstract][Full Text] [Related]
5. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
Ma F; Zhang J; Zhang J; Zhang C
Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
[TBL] [Abstract][Full Text] [Related]
6. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
7. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
[TBL] [Abstract][Full Text] [Related]
8. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy.
Kim JY; Kim YJ; Kim JS; Ryu HS; Lee HK; Kang JS; Kim HM; Hong JT; Kim Y; Han SB
Cancer Lett; 2011 Dec; 313(2):226-34. PubMed ID: 21974804
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.
Pizzurro GA; Tapia IJ; Sganga L; Podhajcer OL; Mordoh J; Barrio MM
Cancer Immunol Immunother; 2015 Nov; 64(11):1393-406. PubMed ID: 26197849
[TBL] [Abstract][Full Text] [Related]
12. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
[TBL] [Abstract][Full Text] [Related]
13. Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
Zhang W; Okimura T; Xu L; Zhang L; Oda T; Kwak M; Yu Q; Jin JO
Oncotarget; 2016 Apr; 7(15):19284-98. PubMed ID: 27008707
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
15. Exogenous dendritic cell homing to draining lymph nodes can be boosted by mast cell degranulation.
Ren SR; Xu LB; Wu ZY; Du J; Gao MH; Qu CF
Cell Immunol; 2010; 263(2):204-11. PubMed ID: 20435302
[TBL] [Abstract][Full Text] [Related]
16. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
17. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
18. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Adams S; O'Neill DW; Nonaka D; Hardin E; Chiriboga L; Siu K; Cruz CM; Angiulli A; Angiulli F; Ritter E; Holman RM; Shapiro RL; Berman RS; Berner N; Shao Y; Manches O; Pan L; Venhaus RR; Hoffman EW; Jungbluth A; Gnjatic S; Old L; Pavlick AC; Bhardwaj N
J Immunol; 2008 Jul; 181(1):776-84. PubMed ID: 18566444
[TBL] [Abstract][Full Text] [Related]
19. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod enhances DNFB mediated contact hypersensitivity in mice.
Ren S; Wang Q; Zhang Y; Zhang B; Zhao C; Dong X; Song Y; Zhang W; Qin X; Liu M
Int Immunopharmacol; 2019 Jul; 72():284-291. PubMed ID: 31005038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
